REGENERON PHARMACEUTICALS, INC. (REGN) Research

Forward Estimates

EPS Estimates

Current Qtr

$10.85

$8.27$13.25

vs $12.89-15.8%

23 analysts

Next Qtr

$13.08

$8.88$17.10

vs $11.83+10.6%

23 analysts

Current Yr

$46.25

$37.15$53.61

vs $44.31+4.4%

29 analysts

Next Yr

$48.10

$40.93$60.05

vs $38.63+24.5%

10 analysts

Revenue Estimates

Current Qtr

$3.81B

$3.54B$4.19B

vs $3.68B+3.8%

21 analysts

Next Qtr

$4.19B

$3.71B$4.75B

vs $3.75B+11.5%

20 analysts

Current Yr

$15.88B

$14.63B$17.19B

vs $14.34B+10.7%

27 analysts

Next Yr

$17.55B

$16.21B$19.09B

vs $15.88B+10.5%

26 analysts

SEC filings →

View all 10-K, 10-Q, and 8-K filings for REGN on EDGAR.

REGN filing events and research context
Filed	Item	Context
Apr 29, 2026	mda_quarterly	Regeneron faces significant commercial headwinds as its flagship ophthalmology franchise, EYLEA and EYLEA HD, confronts intensifying biosimilar competition in the United States following the expiration of regulatory exclusivity in May 2024. While the company continues to pursue clinical enhancements, such as the EYLEA HD pre-filled syringe, the ability of these products to offset revenue erosion from biosimilars and off-label use of compounded bevacizumab remains uncertain. The company’s financial performance is heavily concentrated in its Antibody Collaboration with Sanofi, particularly for Dupixent, which accounted for 45% of total revenue in the first quarter of 2026. This reliance creates substantial risk; any disruption in the commercialization of Dupixent or a breakdown in the partnership—currently strained by ongoing litigation—would materially harm Regeneron’s financial condition. Beyond product-specific risks, Regeneron is navigating a complex regulatory and pricing environment. The company has entered into U.S. Government Agreements to mitigate tariff impacts through 2029, but these commitments, alongside the Inflation Reduction Act’s Medicare drug price negotiation provisions, exert downward pressure on pricing and margins. Furthermore, the company faces ongoing challenges in manufacturing, including recent FDA Complete Response Letters related to third-party fill/finish inspections, which have delayed key product launches and clinical development programs.
Feb 4, 2026	business	Regeneron’s financial performance is heavily dependent on EYLEA, EYLEA HD, and Dupixent, with the Sanofi-collaborated Dupixent accounting for 41% of total revenues in 2025. The company faces intensifying competition from EYLEA biosimilars, including Amgen’s Pavblu, and various JAK inhibitors and antibodies targeting Dupixent’s indications. Revenue is further pressured by U.S. healthcare reforms, specifically the Inflation Reduction Act’s Medicare Drug Price Negotiation Program and proposed "most-favored-nation" pricing models. Operational risks include significant customer concentration, with two distributors representing 77% of gross product revenue in 2025, and a reliance on Bayer for EYLEA’s non-U.S. commercialization. Regulatory challenges are highlighted by recent FDA Complete Response Letters (CRLs) for odronextamab and the EYLEA HD pre-filled syringe, primarily due to third-party manufacturing cGMP compliance issues. Furthermore, Regeneron is currently litigating with Sanofi over the Antibody Collaboration. While expanding its independent international presence through Libtayo and Lynozyfic, the company remains exposed to the high costs of biologic production and a volatile intellectual property environment.
Feb 4, 2026	mda	Regeneron’s financial performance is heavily concentrated in Dupixent, which accounted for 41% of 2025 revenues, and the EYLEA franchise, representing 31%. EYLEA U.S. net sales declined 42% in 2025, driven by competitive pressures and the launch of biosimilars such as Amgen’s Pavblu. To offset this, the company is pivoting to EYLEA HD, which recently received FDA approval for RVO and a four-week dosing regimen. However, manufacturing failures at third-party provider Catalent resulted in Complete Response Letters (CRLs) for the EYLEA HD pre-filled syringe and Ordspono, delaying their commercial timelines. In the clinical pipeline, Lynozyfic is now approved for relapsed/refractory multiple myeloma, and Garetosmab met its Phase 3 primary endpoint for FOP. Conversely, itepekimab yielded mixed Phase 3 results in COPD. Key systemic risks include the Inflation Reduction Act’s drug price negotiation program and significant customer concentration, with two distributors representing 77% of total gross product revenue. While collaborations with Sanofi and Bayer remain central to global commercialization, Regeneron is currently engaged in litigation with Sanofi regarding access to material commercial information for Dupixent.

Filed

Item

Context

Apr 29, 2026

mda_quarterly

Regeneron faces significant commercial headwinds as its flagship ophthalmology franchise, EYLEA and EYLEA HD, confronts intensifying biosimilar competition in the United States following the expiration of regulatory exclusivity in May 2024. While the company continues to pursue clinical enhancements, such as the EYLEA HD pre-filled syringe, the ability of these products to offset revenue erosion from biosimilars and off-label use of compounded bevacizumab remains uncertain. The company’s financial performance is heavily concentrated in its Antibody Collaboration with Sanofi, particularly for Dupixent, which accounted for 45% of total revenue in the first quarter of 2026. This reliance creates substantial risk; any disruption in the commercialization of Dupixent or a breakdown in the partnership—currently strained by ongoing litigation—would materially harm Regeneron’s financial condition. Beyond product-specific risks, Regeneron is navigating a complex regulatory and pricing environment. The company has entered into U.S. Government Agreements to mitigate tariff impacts through 2029, but these commitments, alongside the Inflation Reduction Act’s Medicare drug price negotiation provisions, exert downward pressure on pricing and margins. Furthermore, the company faces ongoing challenges in manufacturing, including recent FDA Complete Response Letters related to third-party fill/finish inspections, which have delayed key product launches and clinical development programs.

Feb 4, 2026

business

Regeneron’s financial performance is heavily dependent on EYLEA, EYLEA HD, and Dupixent, with the Sanofi-collaborated Dupixent accounting for 41% of total revenues in 2025. The company faces intensifying competition from EYLEA biosimilars, including Amgen’s Pavblu, and various JAK inhibitors and antibodies targeting Dupixent’s indications. Revenue is further pressured by U.S. healthcare reforms, specifically the Inflation Reduction Act’s Medicare Drug Price Negotiation Program and proposed "most-favored-nation" pricing models. Operational risks include significant customer concentration, with two distributors representing 77% of gross product revenue in 2025, and a reliance on Bayer for EYLEA’s non-U.S. commercialization. Regulatory challenges are highlighted by recent FDA Complete Response Letters (CRLs) for odronextamab and the EYLEA HD pre-filled syringe, primarily due to third-party manufacturing cGMP compliance issues. Furthermore, Regeneron is currently litigating with Sanofi over the Antibody Collaboration. While expanding its independent international presence through Libtayo and Lynozyfic, the company remains exposed to the high costs of biologic production and a volatile intellectual property environment.

Feb 4, 2026

mda

Regeneron’s financial performance is heavily concentrated in Dupixent, which accounted for 41% of 2025 revenues, and the EYLEA franchise, representing 31%. EYLEA U.S. net sales declined 42% in 2025, driven by competitive pressures and the launch of biosimilars such as Amgen’s Pavblu. To offset this, the company is pivoting to EYLEA HD, which recently received FDA approval for RVO and a four-week dosing regimen. However, manufacturing failures at third-party provider Catalent resulted in Complete Response Letters (CRLs) for the EYLEA HD pre-filled syringe and Ordspono, delaying their commercial timelines. In the clinical pipeline, Lynozyfic is now approved for relapsed/refractory multiple myeloma, and Garetosmab met its Phase 3 primary endpoint for FOP. Conversely, itepekimab yielded mixed Phase 3 results in COPD. Key systemic risks include the Inflation Reduction Act’s drug price negotiation program and significant customer concentration, with two distributors representing 77% of total gross product revenue. While collaborations with Sanofi and Bayer remain central to global commercialization, Regeneron is currently engaged in litigation with Sanofi regarding access to material commercial information for Dupixent.

Forward Estimates

REGN filing events and research context

Keep researching REGN

Related tickers

Related explainers

Forward Estimates